The boulevard of broken IPO dreams
Dollars may be sluicing into biotechnology via venture investments and acquisitions these days, but there’s still one place that private biotechs can’t seem to catch a break, and that’s in the public markets.
The latest casualty here is PTC Therapeutics, which on Friday withdrew an IPO it first filed over a year ago. The company blandly ascribed its request to “market conditions,” and CEO Stuart Peltz told VentureWire (subscription required) that he considers the withdrawal… Continue Reading